Correction to December 2021 Consolidated Revenue
and Full Year 2021 Accumulated Revenue Announcement
Date of events
2022/03/08
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/03/08
2.Company name:PharmaEngine Inc.
3.Relationship to the Company (please enter "head
office" or "subsidiaries"):The company itself
4.Reciprocal shareholding ratios:Not applicable
5.Cause of occurrence:Correct the company's consolidated revenue amount of
December 2021 due to error.
6.Information items/ statements to be corrected:single month consolidated
revenue.
7.Amounts/ contents/ number of page to be corrected:
December 2021 single month consolidated revenue is thousand NT$ 134,525;
Full year 2021 consolidated revenue is thousand NT$ 624,739.
8.Amounts/ contents/ number of page after correction:
December 2021 single month consolidated revenue is thousand NT$ 164,261;
Full year 2021 consolidated revenue is thousand NT$ 654,835.
9.Countermeasures:The updated consolidated revenue figures will be
re-uploaded after the material information is announced on MOPS.
10.Any other matters that need to be specified:NA
Attachments
Original Link
Original Document
Permalink
Disclaimer
PharmaEngine Inc. published this content on 08 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 March 2022 10:20:06 UTC.
PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,
PHARMAENGINE, INC. 
